Acute Myocardial InfarctionNCT02806102
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
An observational study of Acute Myocardial Infarction and Percutaneous Coronary Intervention, run by Seoul St. Mary's Hospital at 2 sites in South Korea.
Trial summary
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events
- What is being tested?
- Percutaneous coronary intervention and Dual-antiplatelet therapy
- Type of treatment
- Surgery or procedure
- How many people
- 13,000 participants
- Where
- 2 sitesSouth Korea
- Study dates
- Jan 2004to Feb 2018
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Acute myocardial infarction who were treated with percutaneous coronary intervention
Who may be able to join
- Acute myocardial infarction who were treated with percutaneous coronary intervention using stents
Who cannot join
- Acute myocardial infarction who were treated with only balloon angioplasty
- Acute myocardial infarction who were managed by conservative strategy
Trial locations and contacts
2 sites in 1 country.
South Korea2 sites, 2 recruiting
- Recruiting
Chonnam National University Hospital
Gwangju
Youngkeun Ahn, MD, PhD, 82-62-220-6263, cecilyk@chonnam.ac.kr
- Recruiting
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul
Kiyuk Chang, MD, PhD, 82-2-2258-1139, kiyuk@catholic.ac.kr
Kiyuk Chang, MD, PhD
About this study
Official title: Cardiovascular Risk and Identification of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction II (COREA-AMI II)
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention.
In addition, this study will identify which baseline clinical, angiographic, or treatment factors are associated with residual cardiovascular risk and bleeding events
Read the detailed description
COREA-AMI registry was conducted previously (NCT02385682) and enrolled consecutive all patient with acute myocardial infarction who were treated with percutaneous coronary intervention from Jan 2004 to Dec 2009.
COREA-AMI II registry extend the enrollment period to Aug 2014 and the follow-up period to Jun 2016.
All consecutive acute myocardial infarction patients had been enrolled prospectively in prior registries of each university hospitals. Eight hospitals of the Catholic University of Korea already have web-based coronary intervention registry (NCT01239914). And Cheonnam University Hospital is one of leading hospitals to design and manage the web-based previous Korean nationwide myocardial infarction registry, the Korea Acute Myocardial Infarction Registry (KAMIR) (http://www.kamir.or.kr/).
Using these previous data, the current registry update new clinical and angiographic variables and assess long-term clinical follow-up data retrospectively. All data were collected on web-based system after eliminating personal information. (http://www.ecrf.kr/coreaami/)
All data are going to be sealed with code by Clinical Research Coordinating Center of the Catholic University of Korea and to be managed and analyzed by independent statistics perssonels.
Cardiovascular center with high-volume percutaneous coronary intervention of following hospitals were participated.
- Seoul St. Mary's Hospital, Seoul, South Korea
- Yeoido St. Mary's Hospital, Seoul, South Korea
- Uijongbu St. Mary's Hospital, Gyeonggi-do, South Korea
- St. Paul Hospital, Seoul, South Korea
- Bucheon St. Mary's Hospital, Gyeonggi-do, South Korea
- Incheon St. Mary's Hospital, Incheon, South Korea
- St. Vincent Hospital, Gyeonggi-do, South Korea
- Deajon St. Mary's Hospital, Daejeon, South Korea
- Cheonnam University Hospital, Gwangju, South Korea
- Conditions
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events, Bleeding
- Being tested
- Percutaneous coronary intervention, Dual-antiplatelet therapy
- Medical subject headings
- Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Percutaneous coronary interventionProcedure or surgery
Also called PCI
Percutaneous coronary intervention
Dual-antiplatelet therapyDrug
Also called DAPT
Dual AntiPlatelet Therapy
Percutaneous coronary interventionProcedure or surgery
Also called PCI
Percutaneous coronary intervention
Dual-antiplatelet therapyDrug
Also called DAPT
Dual AntiPlatelet Therapy
| Study group | Role | What they receive |
|---|---|---|
| High-risk | Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:
* Age ≥ 65 years
* Diabetes mellitus requiring medication
* Documented history of a second prior presumed spontaneous MI (>1 year ago)
* Documented history of angiographic evidence of multivessel coronary artery disease
* Chronic, non-end stage renal dysfunction Receives: Procedure: Percutaneous coronary intervention; Drug: Dual-antiplatelet therapy | |
| Low-risk | Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors Receives: Procedure: Percutaneous coronary intervention; Drug: Dual-antiplatelet therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative incidence of cardiovascular events
Cardiac death, nonfatal myocardial infarction, or nonfatal stroke
Measured: 5 years
Secondary outcomes (12)
Cumulative incidence of all-cause death
Measured: 5 years
Cumulative incidence of cardiac death
Measured: 5 years
Cumulative incidence of nonfatal myocardial infarction
Measured: 5 years
Cumulative incidence of nonfatal stroke
Measured: 5 years
Cumulative incidence of target lesion revascularization
Measured: 5 years
Cumulative incidence of target vessel revascularization
Measured: 5 years
Cumulative incidence of non-target vessel revascularization
Measured: 5 years
Cumulative incidence of definite/Probable stent thrombosis
Measured: 5 years
Cumulative incidence of hospitalization for heart failure
Measured: 5 years
Cumulative incidence of bleeding defined as the Bleeding Academic Research Consortium definitions type 2, 3, and 5
Measured: 5 years
Bleeding defined as the thrombolysis In Myocardial Infarction major/minor
Measured: 5 years
Cumulative incidence of major adverse cardiac and cerebrovascular events
All-cause death, nonfatal myocardial infarction, nonfatal stroke, or any revascularization
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jun 2016 (estimated)
- Study startJan 2004
- Primary completionFeb 2017 (estimated)
- Study completionFeb 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 13,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Seoul St. Mary's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The Catholic University of Korea, Chonnam National University, AstraZeneca
- Responsible party
- Principal investigator, Kiyuk Chang, Seoul St. Mary's Hospital
- Investigators
- Kiyuk Chang, MD, PhD, Principal investigator, Seoul St. Mary's HospitalYoungkeun Ahn, MD, PhD, Study director, Chonnam National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02806102
- Sponsor's protocol ID
- XC15RSMI0089K
- Status last verified
- Jul 2016
- First submitted
- 31 May 2016
- Last updated
- 6 Jul 2016
- Results posted
- No
Publications
Hyun S, Kim KA, Kim SH, Lee M, Lim S, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Park MW, Chang K, Lee KY. Long-term Impact of Residual Inflammatory Risk in Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Who Achieved Optimal Lipid Control. Korean Circ J. 2026 Aug 5. doi: 10.4070/kcj.2025.0469. Online ahead of print.
PubMed 42773911Kim SH, Lee W, Choo EH, Lee KY, Hwang BH, Choi IJ, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K. Long-term outcomes of premature acute myocardial infarction: impact of multivessel disease. Coron Artery Dis. 2026 Aug 1;37(5):377-384. doi: 10.1097/MCA.0000000000001613. Epub 2026 Jan 20.
PubMed 41555573Kim SH, Choo EH, Kang J, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K, Kim HS. The efficacy and safety of prasugrel in acute coronary syndrome: a propensity-matched Korean cohort study focused on age and weight of patients. BMC Cardiovasc Disord. 2025 Nov 26;25(1):888. doi: 10.1186/s12872-025-05263-w.
PubMed 41299333Kim S, Lee KY, Kim KA, Byeon J, Shin S, Hwang BH, Kim JJ, Choo EH, Kim CJ, Kyoung Sa Y, Park MW, Hyun S, Yoon AH, Ahn Y, Chang K. The role of serum uric acid in survival prediction in patients with acute myocardial infarction accompanied by heart failure with preserved ejection fraction. Front Cardiovasc Med. 2025 Nov 10;12:1622275. doi: 10.3389/fcvm.2025.1622275. eCollection 2025.
PubMed 41293617Kim KA, Kim SH, Lee KY, Yoon AH, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Lim S, Park MW, Yoo KD, Jeon DS, Ahn Y, Jeong MH, Chang K. Predictors and Long-Term Clinical Impact of Heart Failure With Improved Ejection Fraction After Acute Myocardial Infarction. J Am Heart Assoc. 2024 Aug 20;13(16):e034920. doi: 10.1161/JAHA.124.034920. Epub 2024 Aug 19.
PubMed 39158557Lim Y, Kim MC, Ahn JH, Lee SH, Hyun DY, Cho KH, Sim DS, Hong YJ, Kim JH, Jeong MH, Choi IJ, Choo EH, Lim S, Hwang BH, Park MW, Kim CJ, Park CS, Kim HY, Chang K, Ahn Y. Optimal timing of percutaneous coronary intervention for non-ST elevated myocardial infarction with congestive heart failure. Cardiovasc Revasc Med. 2024 Oct;67:87-93. doi: 10.1016/j.carrev.2024.04.295. Epub 2024 Apr 25.
PubMed 38679500Kim KA, Lee JE, Choi IJ, Lee KY, Kim CJ, Park MW, Park CS, Kim HY, Yoo KD, Jeon DS, Jeong MH, Chang K. Effect of Renin-Angiotensin System Blockers in Acute Myocardial Infarction Patients with Acute Kidney Injury. Cardiorenal Med. 2024;14(1):178-190. doi: 10.1159/000538042. Epub 2024 Mar 12.
PubMed 38471483Lee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2023 Aug;12(15):e028976. doi: 10.1161/JAHA.122.028976. Epub 2023 Jul 26.
PubMed 37493020Kim HY, Mok J, Kim JY, Jeon D, Her SH, Park MW, Kim DB, Park CS, Lee JM, Chang K, Jung WS, Ahn Y. Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction With Preserved Left Ventricular Systolic Function. J Cardiovasc Pharmacol. 2023 Jul 1;82(1):52-60. doi: 10.1097/FJC.0000000000001427.
PubMed 37019077Ahn Y, Lee D, Choo EH, Choi IJ, Lim S, Lee KY, Hwang BH, Park MW, Lee JM, Park CS, Kim HY, Yoo KD, Jeon DS, Chung WS, Kim MC, Jeong MH, Ahn Y, Chang K. Association Between Bleeding and New Cancer Detection and the Prognosis in Patients With Myocardial Infarction. J Am Heart Assoc. 2022 Nov 15;11(22):e026588. doi: 10.1161/JAHA.122.026588. Epub 2022 Nov 8.
PubMed 36346059Cho KH, Kim MC, Choo EH, Choi IJ, Lee SN, Park MW, Park CS, Kim HY, Kim CJ, Sim DS, Kim JH, Hong YJ, Jeong MH, Chang K, Ahn Y. Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2022 Sep 6;11(17):e025958. doi: 10.1161/JAHA.122.025958. Epub 2022 Aug 24.
PubMed 36000434Lee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Relationship of Serial High-Sensitivity C-Reactive Protein Changes to Long-term Clinical Outcomes in Stabilised Patients After Myocardial Infarction. Can J Cardiol. 2022 Jan;38(1):92-101. doi: 10.1016/j.cjca.2021.10.007. Epub 2021 Nov 2.
PubMed 34737035
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiovascular Risk and Identification of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction II (COREA-AMI II)
- ClinicalTrials.gov ID
- NCT02806102
- Acronym / sponsor ID
- XC15RSMI0089K
- Conditions
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events, Bleeding
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 13,000 participants (estimated)
- Lead sponsor
- Seoul St. Mary's HospitalUniversity, hospital or other
- Collaborators
- The Catholic University of Korea, Chonnam National University, AstraZeneca
- Study start
- Jan 2004
- Primary completion
- Feb 2017 (estimated)
- Study completion
- Feb 2018 (estimated)
- First posted
- 20 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention.
In addition, this study will identify which baseline clinical, angiographic, or treatment factors are associated with residual cardiovascular risk and bleeding events
Detailed description
COREA-AMI registry was conducted previously (NCT02385682) and enrolled consecutive all patient with acute myocardial infarction who were treated with percutaneous coronary intervention from Jan 2004 to Dec 2009.
COREA-AMI II registry extend the enrollment period to Aug 2014 and the follow-up period to Jun 2016.
All consecutive acute myocardial infarction patients had been enrolled prospectively in prior registries of each university hospitals. Eight hospitals of the Catholic University of Korea already have web-based coronary intervention registry (NCT01239914). And Cheonnam University Hospital is one of leading hospitals to design and manage the web-based previous Korean nationwide myocardial infarction registry, the Korea Acute Myocardial Infarction Registry (KAMIR) (http://www.kamir.or.kr/).
Using these previous data, the current registry update new clinical and angiographic variables and assess long-term clinical follow-up data retrospectively. All data were collected on web-based system after eliminating personal information. (http://www.ecrf.kr/coreaami/)
All data are going to be sealed with code by Clinical Research Coordinating Center of the Catholic University of Korea and to be managed and analyzed by independent statistics perssonels.
Cardiovascular center with high-volume percutaneous coronary intervention of following hospitals were participated.
- Seoul St. Mary's Hospital, Seoul, South Korea
- Yeoido St. Mary's Hospital, Seoul, South Korea
- Uijongbu St. Mary's Hospital, Gyeonggi-do, South Korea
- St. Paul Hospital, Seoul, South Korea
- Bucheon St. Mary's Hospital, Gyeonggi-do, South Korea
- Incheon St. Mary's Hospital, Incheon, South Korea
- St. Vincent Hospital, Gyeonggi-do, South Korea
- Deajon St. Mary's Hospital, Daejeon, South Korea
- Cheonnam University Hospital, Gwangju, South Korea
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High-risk | – | Procedure: Percutaneous coronary intervention, Drug: Dual-antiplatelet therapyAcute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors: * Age ≥ 65 years * Diabetes mellitus requiring medication * Documented history of a second prior presumed spontaneous MI (>1 year ago) * Documented history of angiographic evidence of multivessel coronary artery disease * Chronic, non-end stage renal dysfunction |
| Low-risk | – | Procedure: Percutaneous coronary intervention, Drug: Dual-antiplatelet therapyAcute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Acute myocardial infarction who were treated with percutaneous coronary intervention
Key inclusion criteria (1 listed)
- Acute myocardial infarction who were treated with percutaneous coronary intervention using stents
Key exclusion criteria (2 listed)
- Acute myocardial infarction who were treated with only balloon angioplasty
- Acute myocardial infarction who were managed by conservative strategy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Percutaneous coronary interventionAlso: PCIPercutaneous coronary intervention | Procedure or surgery | High-risk |
| Dual-antiplatelet therapyAlso: DAPTDual AntiPlatelet Therapy | Drug | High-risk |
| Percutaneous coronary interventionAlso: PCIPercutaneous coronary intervention | Procedure or surgery | Low-risk |
| Dual-antiplatelet therapyAlso: DAPTDual AntiPlatelet Therapy | Drug | Low-risk |
Primary outcome
Cumulative incidence of cardiovascular events
Time frame: 5 years
Cardiac death, nonfatal myocardial infarction, or nonfatal stroke
12 secondary outcomes
Cumulative incidence of all-cause death
Time frame: 5 years
Cumulative incidence of cardiac death
Time frame: 5 years
Cumulative incidence of nonfatal myocardial infarction
Time frame: 5 years
Cumulative incidence of nonfatal stroke
Time frame: 5 years
Cumulative incidence of target lesion revascularization
Time frame: 5 years
Cumulative incidence of target vessel revascularization
Time frame: 5 years
Cumulative incidence of non-target vessel revascularization
Time frame: 5 years
Cumulative incidence of definite/Probable stent thrombosis
Time frame: 5 years
Cumulative incidence of hospitalization for heart failure
Time frame: 5 years
Cumulative incidence of bleeding defined as the Bleeding Academic Research Consortium definitions type 2, 3, and 5
Time frame: 5 years
Bleeding defined as the thrombolysis In Myocardial Infarction major/minor
Time frame: 5 years
Cumulative incidence of major adverse cardiac and cerebrovascular events
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2016.
- Derived from this study: PubMed 42773911Hyun S, Kim KA, Kim SH, Lee M, Lim S, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Park MW, Chang K, Lee KY. Long-term Impact of Residual Inflammatory Risk in Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Who Achieved Optimal Lipid Control. Korean Circ J. 2026 Aug 5. doi: 10.4070/kcj.2025.0469. Online ahead of print.
- Derived from this study: PubMed 41555573Kim SH, Lee W, Choo EH, Lee KY, Hwang BH, Choi IJ, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K. Long-term outcomes of premature acute myocardial infarction: impact of multivessel disease. Coron Artery Dis. 2026 Aug 1;37(5):377-384. doi: 10.1097/MCA.0000000000001613. Epub 2026 Jan 20.
- Derived from this study: PubMed 41299333Kim SH, Choo EH, Kang J, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K, Kim HS. The efficacy and safety of prasugrel in acute coronary syndrome: a propensity-matched Korean cohort study focused on age and weight of patients. BMC Cardiovasc Disord. 2025 Nov 26;25(1):888. doi: 10.1186/s12872-025-05263-w.
- Derived from this study: PubMed 41293617Kim S, Lee KY, Kim KA, Byeon J, Shin S, Hwang BH, Kim JJ, Choo EH, Kim CJ, Kyoung Sa Y, Park MW, Hyun S, Yoon AH, Ahn Y, Chang K. The role of serum uric acid in survival prediction in patients with acute myocardial infarction accompanied by heart failure with preserved ejection fraction. Front Cardiovasc Med. 2025 Nov 10;12:1622275. doi: 10.3389/fcvm.2025.1622275. eCollection 2025.
- Derived from this study: PubMed 39158557Kim KA, Kim SH, Lee KY, Yoon AH, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Lim S, Park MW, Yoo KD, Jeon DS, Ahn Y, Jeong MH, Chang K. Predictors and Long-Term Clinical Impact of Heart Failure With Improved Ejection Fraction After Acute Myocardial Infarction. J Am Heart Assoc. 2024 Aug 20;13(16):e034920. doi: 10.1161/JAHA.124.034920. Epub 2024 Aug 19.
- Derived from this study: PubMed 38679500Lim Y, Kim MC, Ahn JH, Lee SH, Hyun DY, Cho KH, Sim DS, Hong YJ, Kim JH, Jeong MH, Choi IJ, Choo EH, Lim S, Hwang BH, Park MW, Kim CJ, Park CS, Kim HY, Chang K, Ahn Y. Optimal timing of percutaneous coronary intervention for non-ST elevated myocardial infarction with congestive heart failure. Cardiovasc Revasc Med. 2024 Oct;67:87-93. doi: 10.1016/j.carrev.2024.04.295. Epub 2024 Apr 25.
- Derived from this study: PubMed 38471483Kim KA, Lee JE, Choi IJ, Lee KY, Kim CJ, Park MW, Park CS, Kim HY, Yoo KD, Jeon DS, Jeong MH, Chang K. Effect of Renin-Angiotensin System Blockers in Acute Myocardial Infarction Patients with Acute Kidney Injury. Cardiorenal Med. 2024;14(1):178-190. doi: 10.1159/000538042. Epub 2024 Mar 12.
- Derived from this study: PubMed 37493020Lee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2023 Aug;12(15):e028976. doi: 10.1161/JAHA.122.028976. Epub 2023 Jul 26.
- Derived from this study: PubMed 37019077Kim HY, Mok J, Kim JY, Jeon D, Her SH, Park MW, Kim DB, Park CS, Lee JM, Chang K, Jung WS, Ahn Y. Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction With Preserved Left Ventricular Systolic Function. J Cardiovasc Pharmacol. 2023 Jul 1;82(1):52-60. doi: 10.1097/FJC.0000000000001427.
- Derived from this study: PubMed 36346059Ahn Y, Lee D, Choo EH, Choi IJ, Lim S, Lee KY, Hwang BH, Park MW, Lee JM, Park CS, Kim HY, Yoo KD, Jeon DS, Chung WS, Kim MC, Jeong MH, Ahn Y, Chang K. Association Between Bleeding and New Cancer Detection and the Prognosis in Patients With Myocardial Infarction. J Am Heart Assoc. 2022 Nov 15;11(22):e026588. doi: 10.1161/JAHA.122.026588. Epub 2022 Nov 8.
- Derived from this study: PubMed 36000434Cho KH, Kim MC, Choo EH, Choi IJ, Lee SN, Park MW, Park CS, Kim HY, Kim CJ, Sim DS, Kim JH, Hong YJ, Jeong MH, Chang K, Ahn Y. Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2022 Sep 6;11(17):e025958. doi: 10.1161/JAHA.122.025958. Epub 2022 Aug 24.
- Derived from this study: PubMed 34737035Lee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Relationship of Serial High-Sensitivity C-Reactive Protein Changes to Long-term Clinical Outcomes in Stabilised Patients After Myocardial Infarction. Can J Cardiol. 2022 Jan;38(1):92-101. doi: 10.1016/j.cjca.2021.10.007. Epub 2021 Nov 2.
Related trials for Acute Myocardial Infarction
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kiyuk Chang, MD, PhD principal investigator
Seoul St. Mary's Hospital
Youngkeun Ahn, MD, PhD study director
Chonnam National University Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction and Percutaneous Coronary Intervention, run by Seoul St. Mary's Hospital at 2 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kiyuk Chang, MD, PhD (82-2-2258-1139, kiyuk@catholic.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative incidence of cardiovascular events (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02806102, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2016.